TO THE EDITOR
Imatinib is a selective inhibitor of ABL, platelet-derived growth factor (PDGF) receptor and c-kit, 1 and yields a significant antileukemic effect in patients with chronic myelogenous leukemia (CML). However, most patients receiving imatinib develop mild-tomoderate side effects, including nausea, vomiting, muscle cramps, myelosuppression, edema, and less commonly, fluid retention. 2, 3 In this study, we present a patient with severe muscle pain and swelling of both thighs. Magnetic resonance imaging (MRI) revealed that the muscle swelling was caused by intramuscular fluid retention.
A 35-year-old male who had been diagnosed with CML in December 1995 was referred to our hospital to receive imatinib therapy. His condition had been controlled by hydroxycarbamide (HU) administration alone, because he had developed depression following interferon-a (IFN-a) administration in July 1996. After ceasing HU treatment, his white blood cell (WBC) count was found to be 18 Â 10 Edema and fluid retention are characteristic side effects of imatinib. 2, 3 The edema is usually mild, localized to the periorbital region or legs, and may respond to diuretics. In rare cases, the fluid retention is more generalized, with pleural and pericardial effusion, ascites, anasarca, severe periorbital and cerebral edema. 4, 5 Our patient developed edema of both thighs, as confirmed by MRI. Muscle edema may manifest in patients with polymyositis and dermatomyositis, mild injuries, infectious myositis, radiation therapy, subacute denervation, compartment syndrome, early myositis ossificans, rhabdomyolysis and sickle cell crisis. 6 The clinical course of our patient excluded these causes from the diagnosis. The mechanism of edema and fluid retention remains unknown. One possible mechanism is via the inhibition of the PDGF receptor, as this receptor regulates interstitial fluid pressure by regulating interaction between cells in the connective tissue and molecules in the extracellular matrix. 4, 7 Inhibition of PDGF receptor on dermal dendrocytes may be the mechanism reponsible for causing the periorbital edema by imatinib. 5 Imatinib also decreases interstitial fluid pressure and increases the capillary-to-interstitium transport rate in subcutaneous tumors in rats by antagonising PDGF-b. 7 The incidence of muscle cramps and myalgia following imatinib therapy is reportedly 49 and 20%, respectively. 3 MRI of effected muscles suggest that the mechanism of these adverse effects may be partly because of intramuscular edema. 
